United Therapeutics
UTHR
367 hedge funds and large institutions have $5.48B invested in United Therapeutics in 2018 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 133 increasing their positions, 127 reducing their positions, and 34 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
15% more capital invested
Capital invested by funds: $4.76B → $5.48B (+$716M)
12% more call options, than puts
Call options by funds: $28.9M | Put options by funds: $25.7M
1.69% more ownership
Funds ownership: 96.91% → 98.6% (+1.7%)
5% more repeat investments, than reductions
Existing positions increased: 133 | Existing positions reduced: 127
2% less funds holding
Funds holding: 374 → 367 (-7)
12% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$48M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$45.6M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$36.5M |
| 4 |
AC
Armistice Capital
New York
|
+$36.1M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$29.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$72M |
| 2 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
-$58.3M |
| 3 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$40.7M |
| 4 |
JP Morgan Chase
New York
|
-$30.2M |
| 5 |
GIM
Greylin Investment Management
Orange,
Virginia
|
-$13.4M |
UTHR Hedge Fund Activity: Q3 2018 in Review
367 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2018, worth a combined $5.48B — up 15% from $4.76B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of UTHR and 30 opened new positions — a net loss of 4 holders — while 127 trimmed existing stakes and 133 added.
The largest buyer was Renaissance Technologies, adding an estimated $48M. The largest seller was Fidelity Investments, cutting an estimated $72M.
- 367 institutional investors held United Therapeutics (UTHR) as of Q3 2018, down from 374 in Q2 2018.
- Funds reported $5.48B of United Therapeutics stock for Q3 2018, up 15% quarter-over-quarter.
- 30 funds opened new United Therapeutics positions in Q3 2018 and 34 closed out, a net change of -4 holders.
- The largest United Therapeutics buyer in Q3 2018 was Renaissance Technologies, an estimated $48M added.
- The largest United Therapeutics seller in Q3 2018 was Fidelity Investments, an estimated $72M sold.
Based on aggregated 13F filings for Q3 2018.